{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:47:53Z","timestamp":1761709673715,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"JSPS KAKENHI","award":["18K09420"],"award-info":[{"award-number":["18K09420"]}]},{"name":"Dokkyo Medical University Grant","award":["2016"],"award-info":[{"award-number":["2016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Doc Ophthalmol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s10633-020-09758-z","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T09:03:36Z","timestamp":1582621416000},"page":"137-147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Changes in cone-driven functions after intravitreal aflibercept injections in patients with age-related macular degeneration"],"prefix":"10.1007","volume":"141","author":[{"given":"Tomoharu","family":"Nishimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8671-2399","authenticated-orcid":false,"given":"Shigeki","family":"Machida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"key":"9758_CR1","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"9758_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57\u201365","journal-title":"Ophthalmology"},{"key":"9758_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS (2014) Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121:193\u2013201","journal-title":"Ophthalmology"},{"key":"9758_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/bjophthalmol-2014-305076","volume":"99","author":"Y Ogura","year":"2015","unstructured":"Ogura Y, Terasaki H, Gomi F, Yuzawa M, Iida T, Honda M, Nishijo K, Sowade O, Komori T, Schmidt-Erfurth U, Simader C, Chong V, VIEW 2 Investigators (2015) Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. Br J Ophthalmol 99:92\u201397","journal-title":"Br J Ophthalmol"},{"key":"9758_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:171\u2013185","journal-title":"Angiogenesis"},{"key":"9758_CR6","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, Chen SJ, Wong TY, Mitchell P, Cheung GCM, Zhang Z, Leal S, Ishibashi T, Investigators PLANET (2018) Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol 136:786\u2013793","journal-title":"JAMA Ophthalmol"},{"key":"9758_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","volume":"144","author":"I Maruko","year":"2007","unstructured":"Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:15\u201322","journal-title":"Am J Ophthalmol"},{"key":"9758_CR8","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00417-007-0575-8","volume":"245","author":"Y Liu","year":"2007","unstructured":"Liu Y, Wen F, Huang S, Luo G, Yan H, Sun Z, Wu D (2007) Subtype lesions of neovascular age-related macular degeneration in Chinese patients. Graefes Arch Clin Exp Ophthalmol 245:1441\u20131445","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"9758_CR9","first-page":"439","volume":"25","author":"Y Miyake","year":"1981","unstructured":"Miyake Y, Yanagida K, Kondo K, Ota I (1981) Subjective scotometry and recording of local electroretinogram and visual evoked response. System with television monitor of the fundus. Jpn J Ophthalmol 25:439\u2013448","journal-title":"Jpn J Ophthalmol"},{"key":"9758_CR10","doi-asserted-by":"crossref","DOI":"10.1007\/4-431-30306-5","volume-title":"Electrodiagnosis of retinal diseases","author":"Y Miyake","year":"2006","unstructured":"Miyake Y (2006) Electrodiagnosis of retinal diseases. Springer, Tokyo"},{"key":"9758_CR11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/IAE.0000000000001225","volume":"37","author":"K Takayama","year":"2017","unstructured":"Takayama K, Kaneko H, Ueno S, Maruko R, Piao CH, Yasuda S, Kawano K, Ito Y, Terasaki H (2017) Evaluation of short-term outcomes of intravitreal aflibercept injections for age-related macular degeneration using focal macular electroretinography. Retina 37:553\u2013560","journal-title":"Retina"},{"key":"9758_CR12","first-page":"1073","volume":"6","author":"T Nishimura","year":"2012","unstructured":"Nishimura T, Machida S, Harada T, Kurosaka D (2012) Retinal ganglion cell function after repeated intravitreal injections of ranibizumab in patients with age-related macular degeneration. Clin Ophthalmol 6:1073\u20131082","journal-title":"Clin Ophthalmol"},{"key":"9758_CR13","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/bies.20092","volume":"26","author":"E Storkebaum","year":"2004","unstructured":"Storkebaum E, Lambrechts D, Carmeliet P (2004) VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 26:943\u2013954","journal-title":"Bioessays"},{"key":"9758_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","volume":"171","author":"K Nishijima","year":"2007","unstructured":"Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171:53\u201367","journal-title":"Am J Pathol"},{"key":"9758_CR15","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/bjophthalmol-2013-304019","volume":"98","author":"S Julien","year":"2014","unstructured":"Julien S, Biesemeier A, Taubitz T, Schraermeyer U (2014) Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol 98:813\u2013825","journal-title":"Br J Ophthalmol"},{"key":"9758_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ophtha.2015.10.039","volume":"123","author":"H Koizumi","year":"2016","unstructured":"Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, Okada AA, Iida T (2016) Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month results. Ophthalmology 123:617\u2013624","journal-title":"Ophthalmology"},{"key":"9758_CR17","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1152\/physrev.00021.2004","volume":"85","author":"O Strauss","year":"2005","unstructured":"Strauss O (2005) The retinal pigment epithelium in visual function. Physiol Rev 85:845\u2013881","journal-title":"Physiol Rev"},{"key":"9758_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000477448","volume":"238","author":"Y Oshima","year":"2017","unstructured":"Oshima Y, Kimoto K, Yoshida N, Fujisawa K, Sonoda S, Kubota T, Murata T, Sakamoto T, Yoshida S, Sonoda KH, Ishibashi T (2017) One-year outcomes following intravitreal aflibercept for polypoidal choroidal vasculopathy in Japanese patients: the APOLLO study. Ophthalmologica 238:163\u2013171","journal-title":"Ophthalmologica"},{"key":"9758_CR19","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.ophtha.2015.05.024","volume":"122","author":"A Yamamoto","year":"2015","unstructured":"Yamamoto A, Okada AA, Kano M, Koizumi H, Saito M, Maruko I, Sekiryu T, Iida T (2015) One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology 122:1866\u20131872","journal-title":"Ophthalmology"},{"key":"9758_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00417-016-3489-5","volume":"255","author":"JE Lee","year":"2017","unstructured":"Lee JE, Shin JP, Kim HW, Chang W, Kim YC, Lee SJ, Chung IY, Lee JE, VAULT Study Group (2017) Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study. Graefes Arch Clin Exp Ophthalmol 255:493\u2013502","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"9758_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","volume":"122","author":"K Berg","year":"2015","unstructured":"Berg K, Pedersen TR, Sandvik L, Bragad\u00f3ttir R (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122:146\u2013152","journal-title":"Ophthalmology"},{"key":"9758_CR22","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s00417-017-3718-6","volume":"255","author":"M Morimoto","year":"2017","unstructured":"Morimoto M, Matsumoto H, Mimura K, Akiyama H (2017) Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 255:1891\u20131897","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"9758_CR23","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.ophtha.2018.01.012","volume":"125","author":"SD Adrean","year":"2018","unstructured":"Adrean SD, Chaili S, Ramkumar H, Pirouz A, Grant S (2018) Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF Injections using a treat-extend-stop protocol. Ophthalmology 125:1047\u20131053","journal-title":"Ophthalmology"},{"key":"9758_CR24","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1167\/iovs.15-17279","volume":"56","author":"Y Niwa","year":"2015","unstructured":"Niwa Y, Kakinoki M, Sawada T, Wang X, Ohji M (2015) Ranibizumab and aflibercept: intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaque eyes. Invest Ophthalmol Vis Sci 56:6501\u20136505","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9758_CR25","first-page":"1419","volume":"92","author":"Y Miyake","year":"1988","unstructured":"Miyake Y (1988) Studies on local macular ERG. Acta Soc Ophthalmol Jpn 92:1419\u20131449","journal-title":"Acta Soc Ophthalmol Jpn"},{"key":"9758_CR26","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1167\/iovs.08-1946","volume":"49","author":"S Machida","year":"2008","unstructured":"Machida S, Toba Y, Ohtaki A, Gotoh Y, Kaneko M, Kurosaka D (2008) Photopic negative response of focal electroretinogram in glaucomatous eyes. Invest Ophthalmol Vis Sci 49:5636\u20135644","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9758_CR27","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00417-014-2779-z","volume":"253","author":"T Nishimura","year":"2015","unstructured":"Nishimura T, Machida S, Hashizume K, Kurosaka D (2015) Structures affecting recovery of macular function in patients with age-related macular degeneration after intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 253:1201\u20131209","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"9758_CR28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/bjo.2007.134874","volume":"92","author":"MW Stewart","year":"2008","unstructured":"Stewart MW, Rosenfeld PJ (2008) Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 92:667\u2013668","journal-title":"Br J Ophthalmol"},{"key":"9758_CR29","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, Weisberger A, Lim TH (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32:1453\u20131464","journal-title":"Retina"},{"key":"9758_CR30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/cne.902920402","volume":"292","author":"CA Curcio","year":"1990","unstructured":"Curcio CA, Sloan KR, Kalina RE, Hendrickson AE (1990) Human photoreceptor topography. J Comp Neurol 292:497\u2013523","journal-title":"J Comp Neurol"},{"key":"9758_CR31","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1167\/iovs.04-0458","volume":"45","author":"NV Rangaswamy","year":"2004","unstructured":"Rangaswamy NV, Frishman LJ, Dorotheo EU, Schiffman JS, Bahrani HM, Tang RA (2004) Photopic ERGs in patients with optic neuropathies: comparison with primate ERGs after pharmacologic blockade of inner retina. Invest Ophthalmol Vis Sci 45:3827\u20133837","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9758_CR32","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/IAE.0b013e3181cafc8f","volume":"30","author":"KB Pedersen","year":"2010","unstructured":"Pedersen KB, M\u00f8ller F, Sj\u00f8lie AK, Andr\u00e9asson S (2010) Electrophysiological assessment of retinal function during 6\u00a0months of bevacizumab treatment in neovascular age-related macular degeneration. Retina 30:1025\u20131033","journal-title":"Retina"},{"key":"9758_CR33","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1167\/iovs.06-0849","volume":"47","author":"TD Lamb","year":"2006","unstructured":"Lamb TD, Pugh EN Jr (2006) Phototransduction, dark adaptation, and rhodopsin regeneration the proctor lecture. Invest Ophthalmol Vis Sci 47:5137\u20135152","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9758_CR34","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1167\/iovs.07-0887","volume":"49","author":"S Machida","year":"2008","unstructured":"Machida S, Gotoh Y, Toba Y, Ohtaki A, Kaneko M, Kurosaka D (2008) Correlation between photopic negative response and retinal nerve fiber layer thickness and optic disc topography in glaucomatous eyes. Invest Ophthalmol Vis Sci 49:2201\u20132207","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9758_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10633-018-9638-x","volume":"136","author":"L Frishman","year":"2018","unstructured":"Frishman L, Sustar M, Kremers J, McAnany JJ, Sarossy M, Tzekov R, Viswanathan S (2018) ISCEV extended protocol for the photopic negative response (PhNR) of the full-field electroretinogram. Doc Ophthalmol 136:207\u2013211","journal-title":"Doc Ophthalmol"}],"container-title":["Documenta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10633-020-09758-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10633-020-09758-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10633-020-09758-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T15:29:37Z","timestamp":1695828577000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10633-020-09758-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,25]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["9758"],"URL":"https:\/\/doi.org\/10.1007\/s10633-020-09758-z","relation":{},"ISSN":["0012-4486","1573-2622"],"issn-type":[{"type":"print","value":"0012-4486"},{"type":"electronic","value":"1573-2622"}],"subject":[],"published":{"date-parts":[[2020,2,25]]},"assertion":[{"value":"5 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Shigeki Machida has received research grants from Bayer Yakuhin, Ltd. (Bayer).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with ethical standards of Dokkyo Medical University Saitama Medical Center and with 1964 Helsinki Declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human rights"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement on the welfare of animals"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of Dokkyo Medical University Saitama Medical Center and with the 1964 Helsinki Declaration and later amendments or comparable ethical standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}